Hasnain Faheem 4

What Happened

• Hasnain Faheem, a director of Kura Oncology (KURA), was granted 35,000 derivative shares (reported as an award/acquisition) on 2026-06-04. The grant is reported at $0.00 cash paid (i.e., no purchase price on filing). This is an equity award rather than a market purchase or sale.

Key Details

• Transaction date: 2026-06-04; transaction type: A (award/acquisition of a derivative security).
• Amount granted: 35,000 shares; reported price: $0.00; reported total value at grant: $0 (per filing format).
• Vesting: The award vests in full on the one-year anniversary of the grant (footnote F1).
• Shares owned after transaction: Not specified in the provided filing details.
• Filing timeliness: Reported on 2026-06-04 for the same-date transaction — filing appears timely.

Context

• This filing reflects an equity award to a director, a common compensation practice for alignment with shareholders. Because the award vests in one year and is a derivative (not a market purchase), it does not represent an immediate buy or sell of stock. Retail investors should view such grants as compensation-related rather than an explicit trading signal.